Last 3.80 GBp
Change Today +0.025 / 0.66%
Volume 5.1M
RENE On Other Exchanges
As of 11:35 AM 09/1/14 All times are local (Market data is delayed by at least 15 minutes).

reneuron group plc (RENE) Snapshot

3.85 GBp
Previous Close
3.78 GBp
Day High
4.00 GBp
Day Low
3.65 GBp
52 Week High
11/7/13 - 4.15 GBp
52 Week Low
12/23/13 - 2.71 GBp
Market Cap
Average Volume 10 Days
-0.0050 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for RENEURON GROUP PLC (RENE)

Related News

No related news articles were found.

reneuron group plc (RENE) Related Businessweek News

No Related Businessweek News Found

reneuron group plc (RENE) Details

ReNeuron Group plc is engaged in the research and development of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in Phase II clinical trial for the treatment of patients left disabled by the effects of a stroke. The company is also developing ReN009 stem cell therapy candidate that is in Phase I clinical trial to treat critical limb ischaemia; and ReN003 stem cell therapy candidate, which is in pre-clinical trial for the treatment of retinitis pigmentosa. In addition, it develops and markets a range of stem cell lines, including ReNcell VM, a neural cell line derived from the ventral mesencephalon region of the brain; and ReNcell CX that is derived from the cerebral cortex. ReNeuron Group plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

27 Employees
Last Reported Date: 07/12/14
Founded in 1997

reneuron group plc (RENE) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 262.0K GBP
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: 228.0K GBP
Compensation as of Fiscal Year 2014.

reneuron group plc (RENE) Key Developments

Reneuron Group plc Reports Earnings Results for the Year Ended March 31, 2014

ReNeuron Group plc reported earnings results for the year ended March 31, 2014. For the year, the company reported revenue: royalty income of GBP 22,000 against GBP 17,000 a year ago. Operating loss was GBP 7,969,000 against GBP 7,088,000 a year ago. Loss before income tax was GBP 7,820,000 against GBP 7,059,000 a year ago. Loss and total comprehensive loss for the year was GBP 7,066,000 against GBP 6,345,000 a year ago. Basic and diluted loss per ordinary share was 0.5 pence against 0.8 pence a year ago. Cash used in operating activities was GBP 6,004,000 against GBP 6,022,000 a year ago. Capital expenditure was GBP 121,000 against GBP 37,000 a year ago.

ReNeuron Group plc to Report Fiscal Year 2014 Results on Jun 18, 2014

ReNeuron Group plc announced that they will report fiscal year 2014 results on Jun 18, 2014

ReNeuron Group plc, 2014 Earnings Call, Jun 18, 2014

ReNeuron Group plc, 2014 Earnings Call, Jun 18, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RENE:LN 3.80 GBp +0.025

RENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.87 USD 0.00
Advanced Cell Technology Inc $8.00 USD +0.16
BioTime Inc $3.11 USD +0.13
Geron Corp $2.38 USD +0.05
Neuralstem Inc $4.07 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation RENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.9x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 98.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RENEURON GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at